上市公司股权激励

Search documents
源杰科技: 陕西源杰半导体科技股份有限公司董事会薪酬与考核委员会关于2024年限制性股票激励计划预留授予激励对象名单的核查意见及公示情况说明
Zheng Quan Zhi Xing· 2025-08-08 16:24
Core Viewpoint - The company has publicly disclosed the list of candidates for the 2024 restricted stock incentive plan and confirmed that all candidates meet the necessary legal and regulatory requirements [2][4]. Group 1: Public Disclosure and Verification - The company conducted a public announcement regarding the candidates for the 2024 restricted stock incentive plan, allowing employees to provide feedback during a 10-day public comment period [3]. - No objections were raised by employees during the public comment period regarding the proposed candidates for the incentive plan [3]. - The verification process included checking the candidates' identities, employment contracts, and their roles within the company and its subsidiaries [3]. Group 2: Committee Review and Compliance - The Board's Compensation and Assessment Committee reviewed the candidates' qualifications against relevant laws and regulations, confirming that all listed candidates are eligible for the incentive plan [4]. - The committee ensured that none of the candidates fell under disqualifying conditions as outlined in the applicable laws and regulations [4].
澄星股份: 江苏澄星磷化工股份有限公司董事会薪酬与考核委员会关于公司2025年限制性股票激励计划首次授予激励对象名单的公示情况说明及核查意见
Zheng Quan Zhi Xing· 2025-08-08 16:23
Core Viewpoint - Jiangsu Chengxing Phosphate Chemical Co., Ltd. has announced the public disclosure and verification opinions regarding the list of incentive objects for its 2025 restricted stock incentive plan, ensuring compliance with relevant regulations and confirming the legitimacy of the proposed recipients [1][2][3]. Group 1: Public Disclosure of Incentive Objects - The company held a board meeting on July 29, 2025, to approve the 2025 restricted stock incentive plan and publicly disclosed the draft and summary of the plan on the Shanghai Stock Exchange website [1]. - From July 30 to August 8, 2025, the company conducted a 10-day internal public disclosure of the names and positions of the proposed incentive objects, allowing employees to provide feedback [2]. - No objections were raised by any organization or individual during the public disclosure period [2]. Group 2: Verification by the Compensation and Assessment Committee - The Compensation and Assessment Committee verified the list of proposed incentive objects, including their identification, employment contracts, positions, and appointment documents [2][3]. - The committee confirmed that the proposed incentive objects meet the qualifications stipulated in the management regulations and company articles [3]. Group 3: Committee's Verification Opinions - The committee stated that the basic information of the proposed incentive objects is accurate and does not contain any falsehoods or significant omissions [3]. - All proposed incentive objects are current directors, senior management, core management, key employees, and high-potential talents at the time of the announcement [3]. - The proposed incentive objects do not include independent directors, supervisors, or shareholders holding more than 5% of the company's shares [3].
中望软件: 关于调整2024年限制性股票激励计划授予价格及授予数量的公告
Zheng Quan Zhi Xing· 2025-08-07 11:23
证券代码:688083 证券简称:中望软件 公告编号:2025-045 广州中望龙腾软件股份有限公司 关于调整 2024 年限制性股票激励计划 授予价格及授予数量的公告 本公司董事会及全体董事保证本公告内容不存在虚假记载、误导性陈述 或者重大遗漏,并对其内容的真实性、准确性和完整性依法承担法律责任。 广州中望龙腾软件股份有限公司(以下简称"公司")于 2025 年 8 月 7 日召 开第六届董事会第十六次会议,审议通过了《关于调整 2024 年限制性股票激励 计划授予价格及授予数量的议案》。根据公司《2024 年限制性股票激励计划(草 案)》(以下简称"本激励计划"或"《激励计划(草案)》")的有关规定及公司 量进行了调整。现将有关事项说明如下: 一、本次限制性股票激励计划已履行的决策程序和信息披露情况 了《关于 <广州中望龙腾软件股份有限公司 ensp="ensp" 年限制性股票激励计划="年限制性股票激励计 划" 草案="草案"> 及其摘要的议案》《关于 <广州中望龙腾软件股份有限公司 ensp="ensp" 年限制性股票激="年限制性股 票激"> 励计划实施考核管理办法>的议案》以及《关于提请股东大会授 ...
济川药业: 国浩律师(上海)事务所关于湖北济川药业股份有限公司 2022 年限制性股票与股票期权激励计划注销部分股票期权并回购注销部分限制性股票之法律意见书
Zheng Quan Zhi Xing· 2025-08-06 09:09
Core Viewpoint - The legal opinion letter from Grandall Law Firm (Shanghai) confirms that Hubei Jichuan Pharmaceutical Co., Ltd. has obtained the necessary approvals and authorizations for the cancellation of certain stock options and the repurchase of restricted stocks, in accordance with relevant laws and regulations [2][12]. Group 1: Approval and Authorization - The company held multiple board meetings and a shareholders' meeting in 2022 and 2023 to approve the incentive plan and related matters, with independent directors providing their consent [5][6][7]. - The legal opinion states that the company has complied with the necessary legal requirements and has conducted thorough verification of the facts and legal issues related to the incentive plan [3][4]. Group 2: Details of Cancellation and Repurchase - The company plans to cancel a total of 264,000 stock options and repurchase 219,000 restricted stocks due to the departure of 9 incentive recipients, and an additional 318,500 stock options and restricted stocks due to the demotion of 22 recipients [9][10]. - The repurchase price for the restricted stocks will be based on the grant price plus interest from the People's Bank of China, with specific prices set for different batches of stocks [10]. Group 3: Funding and Disclosure - The funding for the repurchase will come from the company's own funds, and a dedicated securities account has been established for this purpose [10]. - The company has fulfilled its obligation to disclose information regarding the repurchase and cancellation, with announcements made in accordance with regulatory requirements [11][12].
济川药业: 湖北济川药业股份有限公司关于2022年限制性股票与股票期权激励计划部分限制性股票回购注销实施的公告
Zheng Quan Zhi Xing· 2025-08-06 09:09
公司于 2025 年 4 月 25 日召开第十届董事会第十四次会议,审议通过了《关 于注销部分股票期权并回购注销部分限制性股票的议案》:鉴于 14 名激励对象 离职、1 名激励对象退休,根据本激励计划的相关规定,公司拟注销上述激励对 象已获授但尚未行权的股票期权 65.6 万份(其中首次授予股票期权数量 35.8 万 份,预留授予(第一批)股票期权数量 25.3 万份,预留授予(第二批)股票期 权数量 4.5 万份),拟回购注销上述激励对象已获授但尚未解除限售的限制性股 票 50.6 万股(首次授予限制性股票数量 20.8 万股,预留授予(第一批)限制性股 票数量 25.3 万股,预留授予(第二批)限制性股票数量 4.5 万股)。 证券代码:600566 证券简称:济川药业 公告编号: 2025-061 湖北济川药业股份有限公司 关于 2022 年限制性股票与股票期权激励计划 部分限制性股票回购注销实施的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏,并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示: ?回购注销原因:湖北济川药业股份有限公司(以下简称"公 ...
福莱新材: 北京君合(杭州)律师事务所关于浙江福莱新材料股份有限公司2025年限制性股票激励计划首次授予事项的法律意见书
Zheng Quan Zhi Xing· 2025-07-31 16:15
Core Viewpoint - The legal opinion letter issued by Beijing Junhe (Hangzhou) Law Firm confirms that Zhejiang Fulai New Materials Co., Ltd. has met the necessary legal requirements for its 2025 Restricted Stock Incentive Plan, including approval and authorization processes [1][10]. Group 1: Approval and Authorization - The legal opinion confirms that the approval and authorization for the 2025 Restricted Stock Incentive Plan have been obtained, including the necessary resolutions from the board and the supervisory committee [3][6]. - The supervisory committee has expressed that the incentive plan is beneficial for the company's sustainable development and does not harm the interests of the company and its shareholders [3][5]. Group 2: Granting Conditions - The plan stipulates that 2.19 million shares will be granted to 103 incentive objects at a price of 15.64 yuan per share, with the grant date set for July 31, 2025 [6][8]. - The granting conditions have been met, and the company has taken necessary measures to ensure confidentiality and prevent insider trading related to the incentive plan [6][10]. Group 3: Compliance with Regulations - The granting of shares complies with the relevant laws, regulations, and the company's articles of association, confirming the eligibility of the incentive objects [8][9]. - The legal opinion emphasizes that the company has fulfilled its obligations regarding information disclosure and the registration of the restricted stock grant [10].
浙江朗迪集团股份有限公司监事会关于2024年限制性股票激励计划预留部分授予激励对象名单的公示情况说明及核查意见
Shang Hai Zheng Quan Bao· 2025-07-29 17:36
Core Viewpoint - The announcement details the public disclosure and verification of the list of incentive recipients for the 2024 Restricted Stock Incentive Plan by Zhejiang Landi Group Co., Ltd, ensuring compliance with relevant regulations and confirming the qualifications of the selected individuals [1][4][6]. Group 1: Public Disclosure of Incentive Recipients - On July 18, 2025, the company disclosed the announcement regarding the grant of reserved restricted stocks to the incentive recipients on the Shanghai Stock Exchange website [1]. - The public disclosure period for the names and positions of the incentive recipients was from July 18, 2025, to July 28, 2025, during which employees could provide feedback to the supervisory board [1][2]. Group 2: Verification Process by the Supervisory Board - The supervisory board conducted a verification of the incentive recipients' list, including their identification documents, employment contracts, and positions held within the company and its subsidiaries [3]. - The supervisory board confirmed that the individuals listed met the qualifications as per the Company Law and relevant regulations [4]. Group 3: Supervisory Board's Verification Opinion - The supervisory board stated that all individuals included in the incentive plan met the necessary qualifications and did not fall under any disqualifying conditions outlined in the management regulations [5]. - The board confirmed that the basic information of the incentive recipients was accurate and free from any misleading or concealed information [6].
索菱股份: 关于注销2022年限制性股票与股票期权激励计划部分股票期权的公告
Zheng Quan Zhi Xing· 2025-07-17 16:29
Core Viewpoint - The company announced the cancellation of certain stock options from its 2022 restricted stock and stock option incentive plan, which involves a total of 686,877 stock options that have not been exercised [1][7][8]. Group 1: Approval Process - The company held meetings of the board and supervisory committee to review and approve the cancellation of stock options, ensuring compliance with relevant regulations and obtaining necessary authorizations [1][2][6]. - Independent directors provided their opinions on the proposals related to the incentive plan, affirming the legitimacy of the process [1][6]. Group 2: Details of Cancellation - The cancellation involves 225,000 stock options held by two incentive recipients, with an additional 461,877 stock options being canceled due to not being exercised [7]. - The total number of stock options canceled amounts to 686,877, as authorized by the shareholders at the 2021 annual meeting [7][8]. Group 3: Impact on the Company - The cancellation of stock options is in accordance with the relevant regulations and will not have a significant impact on the company's financial status or operational results [7][8]. - The supervisory committee and independent financial advisors have confirmed that the cancellation aligns with legal requirements and does not harm the interests of the company or its shareholders [8][9].
晶华新材: 上海东方华银律师事务所关于上海晶华胶粘新材料股份有限公司注销部分股票期权与回购注销部分限制性股票之法律意见书
Zheng Quan Zhi Xing· 2025-07-17 10:21
Core Viewpoint - Shanghai Jinhua Adhesive New Materials Co., Ltd. is proceeding with the cancellation of certain stock options and the repurchase of restricted stocks as part of its 2024 incentive plan, following necessary approvals and legal compliance [1][4][11]. Group 1: Approval and Authorization - The 2024 incentive plan, including the cancellation and repurchase of stocks, has been approved by the company's board and relevant committees, with necessary disclosures made [4][6][11]. - The board's authorization allows the company to execute the cancellation and repurchase without needing further shareholder approval [7][11]. Group 2: Cancellation and Repurchase Details - The cancellation involves 30,000 stock options and the repurchase of 32,000 restricted stocks due to the disqualification of two incentive recipients [8][9]. - The repurchase price for the restricted stocks has been adjusted from 4.24 yuan to 4.15 yuan per share, with a total repurchase cost of 132,800 yuan plus interest [9][10]. Group 3: Impact on Share Structure - Following the cancellation and repurchase, the number of restricted shares will decrease from 30,843,372 to 30,811,372, while the total share count will drop from 289,634,661 to 289,602,661 [10][11]. - The changes in share structure will be finalized after the completion of the repurchase and necessary regulatory filings [10][11].
港通医疗: 董事会薪酬与考核委员会关于2025年限制性股票激励计划激励对象名单的公示情况说明及核查意见
Zheng Quan Zhi Xing· 2025-07-14 16:12
Core Viewpoint - The company has approved the 2025 Restricted Stock Incentive Plan and has publicly disclosed the list of proposed incentive recipients, following relevant legal and regulatory requirements [1][2][3]. Disclosure and Verification - The company disclosed the draft of the 2025 Restricted Stock Incentive Plan and related documents on July 1, 2025, on the designated information disclosure website [1]. - The internal public notice of the proposed incentive recipients took place from July 2 to July 11, 2025 [1]. Verification Process - The Board's Compensation and Assessment Committee verified the proposed incentive recipients' qualifications, including their employment contracts and positions within the company [2]. - The verification confirmed that all proposed recipients meet the qualifications set forth by relevant laws and the company's articles of association [3]. Committee's Verification Opinion - The proposed incentive recipients are qualified according to the Company Law and other relevant regulations [3]. - None of the proposed recipients fall under the disqualifying conditions outlined in the management regulations [3]. - The recipients include senior management, middle management, grassroots management, and core technical personnel, excluding major shareholders and independent directors [3].